Technical Articles

From the double-muscle phenotype of myostatin loss-of-function, to the common-brake model where multiple ligands converge on ActRIIA, and on to ligand traps and blocking strategies - this article follows the industrial research logic of ActRIIA-media

ACVR2A (ActRIIA) is a type II serine/threonine kinase receptor of the TGF-beta superfamily. This review covers its molecular features, the activin/myostatin ligand network, SMAD2/3 signaling cascades, and key points in tumor and muscle research.

ActRIIB is the type I receptor kinase for myostatin and activin signaling, writing the 'grow less muscle' instruction into the nucleus. This review covers its receptor structure, signaling axis, disease associations and in vitro research tools.

Growth differentiation factor 8, abbreviated as GDF-8, commonly known as Myostatin in the industry, belongs to the TGF-β superfamily of secreted proteins. It is currently a core and highly popular target in the field of skeletal muscle regulation and was first identified in 1997 by a research team from a mouse skeletal muscle cDNA library.